Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

A Novel Clot Waveform Analysis to Measure the Plasma Coagulation Potency in the Presence of Anti-Fixa/Fx Bispecific Antibody, Emicizumab

Keiji Nogami, MD PhD, Tomoko Matsumoto, PhD, Yuka Tabuchi, Tetsuhiro Soeda, PhD, Nobuo Arai, Takehisa Kitazawa, Hidenari Takaoka, Kunihiro Hattori, PhD, Midori Shima, MD PhD

Blood (2016) 128 (22): 1388.

https://doi.org/10.1182/blood.V128.22.1388.1388

Published: 2016

Journal Articles

Activated FVIII Released from FVIII/VWF Complex Facilitates Thrombus Development Under High Shear Flow Condition

Hiroaki Yaoi, MD, Yasuaki Shida, MD PhD, Takehisa Kitazawa, Kunihiro Hattori, PhD, Midori Shima, MD PhD, Keiji Nogami, MD PhD

Blood (2016) 128 (22): 83.

https://doi.org/10.1182/blood.V128.22.83.83

Published: 2016

Journal Articles

ACE910 Facilitates Its Hemostatic Effect with the Lower Concentration of Factor X Than That Required for Factor VIIa-Driven Coagulation

Koji Yada, MD PhD, Keiji Nogami, MD PhD, Takehisa Kitazawa, DVM, Kunihiro Hattori, PhD, Midori Shima, MD PhD

Blood (2015) 126 (23): 1077.

https://doi.org/10.1182/blood.V126.23.1077.1077

Published: 2015

Journal Articles

Anti-Factor IXa/Factor X Antibody (ACE910) Improves the Coagulation Function in Acquired Hemophilia A ex vivo

Masahiro Takeyama, MD PhD, Keiji Nogami, MD PhD, Tomoko Matsumoto, PhD, Takehisa Kitazawa, DVM, Kunihiro Hattori, PhD, Midori Shima, MD PhD

Blood (2015) 126 (23): 3565.

https://doi.org/10.1182/blood.V126.23.3565.3565

Published: 2015

Journal Articles

Activated Protein C-Catalyzed Factor Va Inactivation Predominantly Contributes to the Downregulation of Coagulation Rather Than Factor VIIIa Inactivation

Koji Yada, MD PhD, Keiji Nogami, MD PhD, Tomoko Matsumoto, PhD, Takehisa Kitazawa, DVM, Kunihiro Hattori, PhD, Midori Shima, MD PhD

Blood (2014) 124 (21): 4222.

https://doi.org/10.1182/blood.V124.21.4222.4222

Published: 2014

Journal Articles

FVIII Heavy Chain Enhances Tenase Activity Induced By FVIIIa Mimicking Bispesific Antibody, ACE910

Hiroaki Minami, MD, Keiji Nogami, MD PhD, Takehisa Kitazawa, DVM, Kunihiro Hattori, PhD, Midori Shima, MD PhD

Blood (2014) 124 (21): 1481.

https://doi.org/10.1182/blood.V124.21.1481.1481

Published: 2014

Journal Articles

Distinct Localization of Coagulation Factor VIII, Von Willebrand Factor and Factor VIIIa-Mimetic Bispecific Antibody Contributing to Thrombus Formation Under Whole Blood Flow Conditions

Yasuaki Shida, MD PhD, Keiji Nogami, MD PhD, Hiroaki Minami, MD, Hiroaki Yaoi, MD, Tomoko Matsumoto, PhD, Takehisa Kitazawa, DVM, Kunihiro Hattori, PhD, Midori Shima, MD PhD

Blood (2014) 124 (21): 1483.

https://doi.org/10.1182/blood.V124.21.1483.1483

Published: 2014

Journal Articles

Hemostatic Effect of a Novel Bispecific Antibody (ACE910) Against Activated Factor IX and Factor X in an Acquired Hemophilia A Model

Atsushi Muto, Takehisa Kitazawa, DVM, Kazutaka Yoshihasi, DVM, PhD, Minako Takeda, DVM, Tetsuhiro Soeda, PhD, Tomoyuki Igawa, PhD, Zenjiro Sampei, Yuichiro Sakamoto, Yukiko Okuyama-Nishida, PhD, Hiroyuki Saito, Yoshiki Kawabe, PhD, Midori Shima, MD, PhD, Akira Yoshioka, MD, PhD, Kunihiro Hattori, PhD

Blood (2012) 120 (21): 42.

https://doi.org/10.1182/blood.V120.21.42.42

Published: 2012

Journal Articles

Generation of a Novel Bispecific Antibody (ACE910) Against Activated Factor IX and Factor X Mimicking the Function of Factor VIII Cofactor Activity

Tomoyuki Igawa, PhD, Zenjiro Sampei, Tetsuhiro Soeda, PhD, Yukiko Okuyama-Nishida, PhD, Chifumi Moriyama, Tetsuya Wakabayashi, Eriko Tanaka, Atsushi Muto, Tetsuo Kojima, PhD, Takehisa Kitazawa, DVM, Kazutaka Yoshihashi, DVM, PhD, Aya Harada, Miho Funaki, Kenta Haraya, Tachibana Tatsuhiko, PhD, Sachiyo Suzuki, Keiko Esaki, Yoshiaki Nabuchi, PhD, Kunihiro Hattori, PhD

Blood (2012) 120 (21): 1126.

https://doi.org/10.1182/blood.V120.21.1126.1126

Published: 2012

Journal Articles

Characterization of an Anti-Factor VIII Monoclonal Antibody with A1 and A3 Epitopes Which Increases Factor VIII Activity.

Masahiro Takeyama, MD, Keiji Nogami, MD,PhD, Tetsuhiro Soeda, phD, Tsukasa Suzuki, phD, Kunihiro Hattori, phD, Kohei Tatsumi, MD, Yuri Fujita, MD, Ichiro Tanaka, MD.PhD, Akira Yoshioka, MD,PhD, Midori Shima, MD,PhD

Blood (2006) 108 (11): 1702.

https://doi.org/10.1182/blood.V108.11.1702.1702

Published: 2006

NARROW

A Novel Clot Waveform Analysis to Measure the Plasma Coagulation Potency in the Presence of Anti-Fixa/Fx Bispecific Antibody, Emicizumab

Activated FVIII Released from FVIII/VWF Complex Facilitates Thrombus Development Under High Shear Flow Condition

ACE910 Facilitates Its Hemostatic Effect with the Lower Concentration of Factor X Than That Required for Factor VIIa-Driven Coagulation

Anti-Factor IXa/Factor X Antibody (ACE910) Improves the Coagulation Function in Acquired Hemophilia A ex vivo

Activated Protein C-Catalyzed Factor Va Inactivation Predominantly Contributes to the Downregulation of Coagulation Rather Than Factor VIIIa Inactivation

FVIII Heavy Chain Enhances Tenase Activity Induced By FVIIIa Mimicking Bispesific Antibody, ACE910

Distinct Localization of Coagulation Factor VIII, Von Willebrand Factor and Factor VIIIa-Mimetic Bispecific Antibody Contributing to Thrombus Formation Under Whole Blood Flow Conditions

Hemostatic Effect of a Novel Bispecific Antibody (ACE910) Against Activated Factor IX and Factor X in an Acquired Hemophilia A Model

Generation of a Novel Bispecific Antibody (ACE910) Against Activated Factor IX and Factor X Mimicking the Function of Factor VIII Cofactor Activity

Characterization of an Anti-Factor VIII Monoclonal Antibody with A1 and A3 Epitopes Which Increases Factor VIII Activity.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only